GLP-1RAs have been shown to clinically decrease major cardiac adverse events in patients with T2DM, likely due to a combination of indirect effects of GLP-1 on glycemic control decreasing systemic inflammation and direct effects on endothelial cell function [14]. Here, GLP1R is linked to type 2 diabetes mellitus.